Two preclinical advances highlight growing sophistication in mRNA therapeutics. A team reported a tumor‑selective modified RNA translation system (SMRTS) that programs mRNA to activate therapeutic genes preferentially in cancer cells using microRNA‑sensing logic; mouse models showed striking tumor selectivity. Separately, researchers described an organ‑targeted mRNA‑encoded bispecific T‑cell engager (BiTE) that delivers an immunotherapy payload to the liver by leveraging tissue‑specific delivery, demonstrating proof‑of‑concept in animal models. Both approaches shift selectivity burden from delivery vehicles to the RNA payload, offering new routes to reduce off‑target toxicity for cancer mRNA therapies.